About the panel: Lisa Beck, MD, is a professor of dermatology and the director of translational research at the University of Rochester Medical Center Department of Dermatology and Medicine in Rochester, New York. Mark Boguniewicz, MD, is an allergy-immunology expert and professor of pediatrics in the Division of Allergy and Clinical Immunology at the National Jewish Health affiliate of University of Colorado School of Medicine in Denver, Colorado. Emma Guttman-Yassky, MD, PhD, is an associate professor of dermatology and immunology at the Icahn School of Medicine at Mount Sinai Hospital in New York and director of the Center for Excellence in Eczema, the Occupational/Contact Dermatitis Clinic, and the Laboratory of Inflammatory Skin Diseases.
Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine. 2015 Jun;73(2):311-318.
Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135(2):324-336.
Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016 Jan;15(1):35-50.
Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012 Dec;130(6):1344-1354.
Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis–part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol. 2011;127(6):1420-1432.
Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016 Mar; 12(387):1109-22.
Sponsored Content: This educational program has been developed by Regeneron Pharmaceuticals and Sanofi Genzyme.